OSRH vs ZJYL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
OSRH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic Current Ratio of 0.16, indicating an inability to meet short-term obligations. The company is experiencing a collapse in top-line growth with revenue declining 58.30% YoY, coupled with an unsustainable operating margin of -1674.81%. While the Price-to-Book ratio of 0.19 suggests deep value, the lack of liquidity and negative earnings trajectory point toward a high risk of insolvency. The single analyst target of $10.00 is completely decoupled from the current fundamental reality.
ZJYL presents a classic 'value trap' scenario, characterized by a stable Piotroski F-Score of 6/9 and a price significantly below its Graham Number ($4.13), yet plagued by severe fundamental decay. While the company maintains a healthy balance sheet with a current ratio of 1.85 and low debt/equity (0.64), it is suffering from catastrophic growth contraction, with revenue down 16.5% and earnings down 32% YoY. The massive 87.7% decline in share price over the last year reflects a market that has completely lost confidence in the company's growth trajectory. Despite trading at a deep discount to book value (P/B 0.57), the lack of positive catalysts and bearish technical trend outweigh the valuation appeal.
Compare Another Pair
Related Comparisons
OSRH vs ZJYL: Head-to-Head Comparison
This page compares OSR Holdings, Inc. (OSRH) and Jin Medical International Ltd. (ZJYL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.